Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr Reddy's Laboratories's other current liabilities for the quarter that ended in Jun. 2026 was ₹17,123 Mil.
Dr Reddy's Laboratories's quarterly other current liabilities
increased
from Dec. 2025 (₹15,854 Mil) to Mar. 2026 (₹23,687 Mil) but then
declined
from Mar. 2026 (₹23,687 Mil) to Jun. 2026 (₹17,123 Mil).
Dr Reddy's Laboratories's annual other current liabilities
increased
from Mar. 2024 (₹11,417 Mil) to Mar. 2025 (₹13,523 Mil) and
increased
from Mar. 2025 (₹13,523 Mil) to Mar. 2026 (₹23,687 Mil).
Dr Reddy's Laboratories Other Current Liabilities Related Terms
Dr Reddy's Laboratories Other Current Liabilities Historical Data
* Premium members only.
The historical data trend for Dr Reddy's Laboratories's Other Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories Other Current Liabilities Chart
Dr Reddy's Laboratories Other Current Liabilities Calculation
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of ₹17,123 Mil mean?
Dr Reddy's Laboratories (NSE:DRREDDY) has a Other Current Liabilities of ₹17,123 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Dr Reddy's Laboratories.
Is Dr Reddy's Laboratories' Other Current Liabilities too high?
Dr Reddy's Laboratories' current Other Current Liabilities is ₹17,123 Mil. Overall, Dr Reddy's Laboratories has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Other Current Liabilities compare to ZTS?
Dr Reddy's Laboratories' Other Current Liabilities of ₹17,123 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Dr Reddy's Laboratories. Dr Reddy's Laboratories's current Other Current Liabilities is ₹17,123 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (NSE:DRREDDY) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,359.00, compared to a current price of ₹1,144.80 — trading 15.8% below its estimated fair value. The current Other Current Liabilities is ₹17,123 Mil. Dr Reddy's Laboratories' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Dr Reddy's Laboratories (NSE:DRREDDY), the current Other Current Liabilities is ₹17,123 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr Reddy's Laboratories (NSE:DRREDDY) Overvalued in 2026?
Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued.
The current stock price of ₹1,144.80 is trading 15.8% below its estimated GF Value™ of ₹1,359.00.
GuruFocus considers Dr Reddy's Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:DRREDDY:
Other Current Liabilities: ₹17,123 Mil
GF Value™: ₹1,359.00 vs. price of ₹1,144.80 (15.8% below fair value)
No single metric tells the full story. See the NSE:DRREDDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
93GF Score
Get the complete analysis for NSE:DRREDDY
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DRREDDY has been successfully added to your 
